Natalizumab Completed Phase 0 Trials for Relapsing Forms of Multiple Sclerosis Treatment

IndicationsStatusPurposePhase
CompletedTreatment0
clinicaltrials.gov IdentifierTitleDrugs
NCT00424788A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)